Black Patients Diagnosed With Huntington's Later Than Whites

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on July 12, 2024.

By Dennis Thompson HealthDay Reporter

FRIDAY, July 12, 2024 -- Black patients with Huntington’s disease receive their diagnoses an average of one year later than white people with the incurable genetic disorder, a new study shows.

Early diagnosis is essential to help patients get proper care and prepare for the effects of the disease, lead researcher Dr. Adys Mendizabal, a UCLA Health assistant professor of neurology, said in a news release.

“The sooner people come into care, the more information they have and the more they can plan,” she said. “Ultimately, we cannot yet change … the progression of the disease but we can definitely change the quality of life that people and their families experience while having the disease.”

Huntington’s causes brain cells to slowly lose function and die, primarily in parts of the brain that regulate movement and memory.

People with the disorder have movement symptoms similar to Parkinson’s disease, such as uncontrolled jerking and twitching, trouble walking and swallowing, as well as slurred speech. They also suffer mood swings and problems with reasoning, remembering and learning.

About 41,000 Americans have the disease and 200,000 are at risk of inheriting it, researchers said in background notes. A child of a parent with Huntington’s disease has a 50/50 chance of inheriting the disorder.

For the study, researchers analyzed data on more than 4,700 Huntington’s disease patients.

They found that Black patients received a Huntington’s diagnosis an average 4.6 years after the first motor symptoms started, compared to 3.7 years for white patients.

The study also found diagnosis delays based on education and income.

Unemployed people were diagnosed 1.3 years later than those with full-time jobs, results show.

And people with a PhD were diagnosed 1.7 years later than those with a high school degree or GED, researchers found.

Researchers also discovered that people who first develop psychiatric symptoms of Huntington’s disease rather than motor symptoms tend to be diagnosed a year later.

Mendizabal said researchers cannot explain these differences, given the data with which they were working.

But delayed diagnoses could affect the underrepresentation of minority groups in clinical trials for treatment, she noted.

“We have a lot of clinical trials in Huntington’s that focus on disease modification, trying to prevent or slow down the onset of symptoms,” Mendizabal said. “But if you know that we have certain subgroups of patients that are experiencing delayed diagnoses or coming in with more severe disease, then they may not be eligible to be part of a clinical trial.”

There also needs to be better tracking of health outcomes of treatment among minority populations, she added.

“In addition to reviewing clinical data, we also need qualitative studies to appropriately understand the experience of minoritized groups with Huntington’s disease both as they navigate the disease, as well as accessing care for a rare disease within our healthcare systems,” Mendizabal said. “Our findings serve as a starting point to create awareness and improve access to care for minoritized groups affected by rare neurological diseases.”

The new study appears in the journal Neurology: Clinical Practice.

Sources

  • UCLA Health, news release, July 9, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-07-13 05:15

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords